Migraine (Adult) Clinical Trials
A listing of Migraine (Adult) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 17 clinical trials
Migraine
A Study to Investigate the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants with Episodic Migraine
- 0 views
- 12 Dec, 2022
- 1 location
Episodic Migraine
We are seeking adult participants for a new migraine clinical research study.This study is to evaluate the tolerability of an FDA approved medication taken once daily as a preventative treatment for migraines.
- 7 views
- 26 Jan, 2023
- 1 location
Chronic Migraine
We are seeking adult participants for a new clinical research study to evaluate the effectiveness of an investigational drug as a preventative treatment for migraines.
- 1 views
- 26 Jan, 2023
- 1 location
![A Phase 3, Randomized, Double-blind,Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM])](/media/imagery/226511.svg)
A Phase 3, Randomized, Double-blind,Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) (OASIS(EM))
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine. The study hypothesis is that in pediatric subjects with episodic migraine, the combined erenumab dose group has a greater reduction from baseline …
- 258 views
- 21 Oct, 2022
- 75 locations
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2 (PIONEER-PEDS2)
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
- 176 views
- 24 Oct, 2022
- 172 locations
A Phase 2/3 Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
- 125 views
- 20 Oct, 2022
- 89 locations
Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Phase 4 Study (EMBRACE)
The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.
- 366 views
- 23 Oct, 2022
- 64 locations
A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of episodic migraine (EM). Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to placebo for the preventive treatment of EM, to evaluate the safety and …
- 126 views
- 04 Oct, 2022
- 74 locations
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine (OASIS (CM))
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine. The study hypothesis is that in pediatric subjects with chronic migraine, the combined erenumab dose group has a greater reduction from baseline …
- 422 views
- 07 Oct, 2022
- 70 locations
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). Secondary objectives are to evaluate the efficacy of subcutaneous fremanezumab in …
- 16 views
- 04 Oct, 2022
- 54 locations
- 1
- 2